NO20020663L - NSAID og EFGR kinase inhibitor inneholdende sammensetning for behandling eller inhibisjon av tarmpolypper og tarmkreft - Google Patents

NSAID og EFGR kinase inhibitor inneholdende sammensetning for behandling eller inhibisjon av tarmpolypper og tarmkreft

Info

Publication number
NO20020663L
NO20020663L NO20020663A NO20020663A NO20020663L NO 20020663 L NO20020663 L NO 20020663L NO 20020663 A NO20020663 A NO 20020663A NO 20020663 A NO20020663 A NO 20020663A NO 20020663 L NO20020663 L NO 20020663L
Authority
NO
Norway
Prior art keywords
bowel
nsaid
inhibition
treatment
kinase inhibitor
Prior art date
Application number
NO20020663A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020663D0 (no
Inventor
Philip Frost
Carolyn Discafani-Marro
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of NO20020663D0 publication Critical patent/NO20020663D0/no
Publication of NO20020663L publication Critical patent/NO20020663L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20020663A 1999-08-12 2002-02-11 NSAID og EFGR kinase inhibitor inneholdende sammensetning for behandling eller inhibisjon av tarmpolypper og tarmkreft NO20020663L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37326199A 1999-08-12 1999-08-12
PCT/US2000/021021 WO2001012227A1 (en) 1999-08-12 2000-08-02 Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer

Publications (2)

Publication Number Publication Date
NO20020663D0 NO20020663D0 (no) 2002-02-11
NO20020663L true NO20020663L (no) 2002-04-09

Family

ID=23471660

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020663A NO20020663L (no) 1999-08-12 2002-02-11 NSAID og EFGR kinase inhibitor inneholdende sammensetning for behandling eller inhibisjon av tarmpolypper og tarmkreft

Country Status (24)

Country Link
EP (1) EP1202746B1 (de)
JP (1) JP2003507342A (de)
KR (1) KR20020018201A (de)
CN (1) CN1229142C (de)
AR (1) AR029763A1 (de)
AT (1) ATE341341T1 (de)
AU (1) AU783116B2 (de)
BR (1) BR0013219A (de)
CA (1) CA2380904C (de)
CZ (1) CZ2002474A3 (de)
DE (1) DE60031127T2 (de)
DK (1) DK1202746T3 (de)
EA (1) EA006876B1 (de)
ES (1) ES2272305T3 (de)
HK (1) HK1042244A1 (de)
HU (1) HUP0203162A3 (de)
IL (1) IL147913A0 (de)
MX (1) MXPA02001448A (de)
NO (1) NO20020663L (de)
NZ (1) NZ517120A (de)
PL (1) PL353267A1 (de)
PT (1) PT1202746E (de)
WO (1) WO2001012227A1 (de)
ZA (1) ZA200201156B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
CN1190197C (zh) * 2000-03-13 2005-02-23 惠氏控股公司 氰基喹啉用于制备治疗或抑制结肠息肉药物中的用途
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
US6706699B2 (en) 2001-06-21 2004-03-16 Ariad Pharmaceuticals, Inc. Quinolines and uses thereof
JP4326328B2 (ja) 2001-07-16 2009-09-02 アストラゼネカ アクチボラグ キノリン誘導体及びそれらのチロシンキナーゼ阻害薬としての使用
IL161462A0 (en) * 2001-10-25 2004-09-27 Novartis Ag Combinations comprising a selective cyclooxygenase-2 inhibitor
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE60313339T2 (de) 2002-07-31 2008-01-03 Critical Outcome Technologies, Inc. Protein tyrosin kinase inhibitoren
ES2298563T3 (es) 2002-10-09 2008-05-16 Critical Outcome Technologies, Inc. Inhibidores de proteinas tirosina cinasas.
AU2003295598B2 (en) * 2002-11-15 2009-12-24 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
PT1740591E (pt) 2004-04-02 2009-09-24 Osi Pharm Inc Inibidores da proteína quinase heterobicíclicos em substituição de anel bicíclico 6,6
JP4205757B2 (ja) 2004-05-06 2009-01-07 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ４−フェニルアミノ−キナゾリン−６−イル−アミド
WO2005117916A1 (en) 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with cisplatin and an egfr-inhibitor
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
KR20090116782A (ko) 2007-02-06 2009-11-11 베링거 인겔하임 인터내셔날 게엠베하 바이사이클릭 헤테로사이클, 당해 화합물을 함유하는 약물, 이의 용도 및 이의 제조방법
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
KR20100111291A (ko) 2008-02-07 2010-10-14 베링거 인겔하임 인터내셔날 게엠베하 스피로사이클릭 헤테로사이클, 상기 화합물을 함유하는 약제, 이의 용도 및 이의 제조 방법
US8088782B2 (en) 2008-05-13 2012-01-03 Astrazeneca Ab Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A
EP2283020B8 (de) 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituierte imidazopyr- und imidazotriazine
WO2010006438A1 (en) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
PL387312A1 (pl) 2009-02-19 2010-08-30 Farma-Projekt Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi
US20120064072A1 (en) 2009-03-18 2012-03-15 Maryland Franklin Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
JP2012524119A (ja) 2009-04-20 2012-10-11 オーエスアイ・ファーマシューティカルズ，エルエルシー Ｃ−ピラジン−メチルアミンの調製
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
BR112013030894A2 (pt) * 2011-06-01 2016-08-16 Janus Biotherapeutics Inc moduladores do sistema imune

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309150A1 (en) * 1997-11-04 1999-05-14 Pfizer Products Inc. Indazole bioisostere replacement of catechol in therapeutically active compounds
HUP0004286A3 (en) * 1997-11-06 2002-01-28 American Cyanamid Co Madison Use of quinazoline derivatives for producing pharmaceutical compositions for treating colonic polyps

Also Published As

Publication number Publication date
MXPA02001448A (es) 2002-07-02
ZA200201156B (en) 2003-05-12
EA200200246A1 (ru) 2002-08-29
DE60031127D1 (de) 2006-11-16
IL147913A0 (en) 2002-08-14
CN1370080A (zh) 2002-09-18
EA006876B1 (ru) 2006-04-28
BR0013219A (pt) 2002-04-23
HUP0203162A2 (hu) 2003-01-28
WO2001012227A1 (en) 2001-02-22
KR20020018201A (ko) 2002-03-07
PT1202746E (pt) 2007-01-31
ES2272305T3 (es) 2007-05-01
DE60031127T2 (de) 2007-02-01
DK1202746T3 (da) 2007-01-02
CZ2002474A3 (cs) 2003-02-12
NZ517120A (en) 2004-10-29
NO20020663D0 (no) 2002-02-11
HUP0203162A3 (en) 2006-07-28
HK1042244A1 (zh) 2002-08-09
CN1229142C (zh) 2005-11-30
EP1202746A1 (de) 2002-05-08
EP1202746B1 (de) 2006-10-04
ATE341341T1 (de) 2006-10-15
PL353267A1 (en) 2003-11-03
JP2003507342A (ja) 2003-02-25
AU6395900A (en) 2001-03-13
AU783116B2 (en) 2005-09-29
CA2380904A1 (en) 2001-02-22
AR029763A1 (es) 2003-07-16
CA2380904C (en) 2009-02-10

Similar Documents

Publication Publication Date Title
NO20020663D0 (no) NSAID og EFGR kinase inhibitor inneholdende sammensetning for behandling eller inhibisjon av tarmpolypper og tarmkreft
NO20024610D0 (no) Synergistiske metoder og blandinger for behandling av kreft
NO20002166D0 (no) Anvendelse av quinazolinderivater som tyrosinkinaseinhibitorer for behandling av kolonpolypper
EE200100717A (et) Indasooliühendid ja farmatseutilised kompositsioonid proteiini kinaaside inhibeerimiseks ja meetodid nende kasutamiseks
NO20021587D0 (no) Sementeringsblandinger og bruk av slike blandinger for sementering av brönner eller lignende
NO20013380L (no) 2-aminobenzoksazinonderivater for behandling av fedme
EE200100659A (et) Diaminotiasoolid ja nende kasutamine proteiinikinaaside pärssimiseks
HUP0400327A3 (en) Azole derivatives having metalloproteinase inhibitor effect pharmaceutical compositions containing them and their use
IL151249A0 (en) Use of cyanoquinolines for treating or inhibiting colonic polyps
NO20014379L (no) Anvendelse av Xenon for behandling av Neurointoksikasjoner
NO20013381D0 (no) 2-oksybenzoksazinonderivater for behandling av fedme
NO20024386L (no) Farmasöytiske sammensetninger av glycogenfosforylase- inhibitorer
NO20020365L (no) Oligonukleotider for inhibiering av ekspresjonen av humant eg5
NO20015516L (no) Preparater og anvendelser av ET743 for behandling av kreft
NO20041214L (no) Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
NO994631D0 (no) Fremgangsmaater og sammensetninger for behandling av eggstokkreft
NO20005680L (no) Kombinasjoner av protein-farnesyltransferase og HMG CoA reduktase inhibitorer og anvendelse derav for behandling av cancer
NO20010464D0 (no) Fremgangsmåter og sammensetninger for behandling av gastroösofrageal-reflukssyndrom
NO993784L (no) Farmasöytiske blandinger inneholdende ibuprofen og domperidon for behandling av migrene
HUP9902119A3 (en) Diphenyl stilbene derivatives as cox-2 inhibitors and pharmaceutical compositions of the same
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
NO20003199D0 (no) Benzo(C)kinolizinderivater og deres anvendelse som 5- <alfa>reduktaseinhibitorer
NO995314D0 (no) For og anvendelse av slikt for
PT1140090E (pt) Utilizacao de fanquinona para o tratamento ou prevencao da perda de memoria
AR028186A1 (es) Compuestos de 5-aril-1, 2, 4-triazol inhibidores de ciclooxigenasa-2 y composiciones farmaceuticas que comprenden dichos compuestos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application